OUR COMPANY
We are striving to improve patients’ quality of life by developing innovative combination products, based on previously approved drugs, with favorable balance between safety and efficacy.
WHAT IS P2B001?
P2B001 is a novel, once-daily combination of extended-release (ER) pramipexole, a low dose dopamine agonist (0.6mg), and rasagiline, a low dose MAO-B inhibitor (0.75mg), developed specifically for the treatment of..
LATEST NEWS
OUR MISSION
We are striving to improve patients’ quality of life by developing innovative combination products, based on previously approved drugs,
with favorable balance between safety and efficacy.
with favorable balance between safety and efficacy.